Diagnostic value and significance of serum APE1 in colorectal cancer

Yuxin YANG; Le HE; Xianfeng LU; Xiao YANG; Zhaoyang ZHONG; Dong WANG; Nan DAI

doi:10.16016/j.1000-5404.201907069

您当前的位置：

首页 >

文章列表页 >

Diagnostic value and significance of serum APE1 in colorectal cancer

Clinical Medicine | 更新时间：2026-01-09

- Diagnostic value and significance of serum APE1 in colorectal cancer
- Journal of Third Military Medical University Vol. 42, Issue 1, Pages: 88-93(2020)
- 作者机构：
  
  400042 重庆，陆军军医大学(第三军医大学)大坪医院肿瘤中心
- 作者简介：
- 基金信息：
  
  the Science and Technology Achievements Transformation Fund of Third Military Medical University(2013XZH01);the Major Special Fund of Clinical Research of Army Military Medical University(2018XLC2016)
- DOI：10.16016/j.1000-5404.201907069
  CLC： R341;R730.43;R735.35
- Received：09 July 2019，
  
  Revised：2019-11-01，
  
  Published：15 January 2020
- 稿件说明：
移动端阅览
Yuxin YANG, Le HE, Xianfeng LU, et al. Diagnostic value and significance of serum APE1 in colorectal cancer[J]. Journal of Third Military Medical University, 2020, 42(1): 88-93.
DOI：

Yuxin YANG, Le HE, Xianfeng LU, et al. Diagnostic value and significance of serum APE1 in colorectal cancer[J]. Journal of Third Military Medical University, 2020, 42(1): 88-93. DOI： 10.16016/j.1000-5404.201907069.

摘要

目的

探讨结直肠癌患者血清APE1蛋白的表达及其在临床诊断中的价值。

方法

利用ELISA法检测本院2010年1月至2015年9月肿瘤中心收治的202例结直肠癌患者和健康体检中心242例健康对照人群血清APE1蛋白的表达水平，通过免疫组化确定相应患者肿瘤组织APE1蛋白的表达特征，同时采用C-12肿瘤蛋白芯片试剂盒检测上述人群CEA的表达水平。分析血清APE1蛋白与肿瘤组织APE1蛋白表达水平及年龄、性别、分期等临床指标的相关性，并绘制受试者工作特征曲线(receiver operating characteristic curve，ROC)评估血清APE1蛋白及CEA在结直肠癌诊断中的应用价值。

结果

202例结直肠癌患者中位血清APE1蛋白浓度为0.331(0.007~4.359)ng/mL，显著高于对照组0.09

1(0~1.374)ng/mL(

0.01)。Spearman相关分析显示血清APE1蛋白水平与肿瘤组织中APE1蛋白表达呈正相关(

=0.331，

=0.025)，而与年龄、性别、分期等指标不相关。ROC曲线显示血清APE1蛋白的AUC为0.799(95%

=0.756~0.843)，灵敏度为76.20%，特异性为76.40%，血清CEA的AUC为0.736(95%

=0.687~0.785)，其灵敏度为51.00%，特异性为99.60%。血清APE1蛋白与CEA联合后其AUC为0.857(95%

=0.819~0.896)，灵敏度和特异性分别为72.30%和91.30%。

结论

结直肠癌患者血清APE1蛋白水平与肿瘤组织APE1表达呈正相关且较健康对照人群显著增高。血清APE1蛋白可与CEA联合作为结直肠癌辅助诊断的血清学标志物。

Abstract

Objective

To investigate the expression of serum apurinic/apyrimidinic endonuclease 1 (APE1) in colorectal cancer and its diagnostic value.

Methods

A total of 202 patients with identified colorectal cancer admitted in our center from January 2010 to September 2015 were recruited in this study

and another 242 healthy volunteers who took physical examination at the same period served as normal control. Their serum APE1 level was quantified by ELISA. The expression of APE1 protein in colorectal cancer tissues was detected by immunohistochemistry. The expression of carcinoembryonic antigen (CEA) was detected by C-12 tumor protein chip kit. The correlations of APE1 protein levels in the serum and tumor tissues with age

gender

clinical stage and other indicators were analyzed. Receiver operating characteristic (ROC) curve was plotted to evaluate the value of serum APE1 and CEA levels in the diagnosis of colorectal cancer.

Results

The serum APE1 level was 0.331 (0.007~4.359) ng/mL in the colorectal cancer patients

which was significantly higher than that in healthy control [0.091(0～1.374) ng/mL

0.001

]

. Spearman correlation analysis showed that the serum APE1 level was positively correlated with its protein expression in colorectal cancer tissues (

=0.331

=0.025)

but had no relatio

ns with age

sex and clinical stages. ROC curve displayed that the area under the curve (AUC) was 0.799 (95%

=0.756~0.843)

the sensitivity was 76.20%

and the specificity was 76.40% for serum APE1 level in the diagnosis. While

the AUC value was 0.736 (95%

=0.687~0.785)

the sensitivity was 51.00%

and the specificity was 99.60% for serum CEA level. Their combination increased the AUC value to 0.857 (95%

=0.819~0.896)

and the sensitivity and accuracy to 72.30% and 91.30%

respectively.

Conclusion

The serum APE1 level is positively correlated with its expression level in the colorectal cancer tissue

and both are significantly higher than those in the health control. Combined detection of serum APE1 and CEA levels might be considered as serum markers in auxiliary diagnosis for colorectal cancer.

关键词

Keywords

references

SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI:10.3322/caac.21551.

CHEN W Q, ZHENG R S, BAADE P D, et al . Cancer statistics in China, 2015[J ] . CA Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.

CHEN W Q, SUN K X, ZHENG R S, et al . Cancer incidence and mortality in China, 2014[J ] . Chin J Cancer Res, 2018, 30(1): 1-12. DOI:10.21147/j.issn.1000-9604.2018.01.01.

DE MAIO G, RENGUCCI C, ZOLI W, et al . Circulating and stool nucleic acid analysis for colorectal cancer diagnosis[J ] . World J Gastroenterol, 2014, 20(4): 957-967. DOI:10.3748/wjg.v20.i4.957.

LI M X, WILSON D M 3rd. Human apurinic/apyrimidinic endonuclease 1[J]. Antioxid Redox Signal, 2014, 20(4): 678-707. DOI:10.1089/ars.2013.5492.

KELLEY M R, GEORGIADIS M M, FISHEL M L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1[J]. Curr Mol Pharmacol, 2012, 5(1): 36-53. DOI: 10. 2174/1874- 470211205010036.

TELL G, FANTINI D, QUADRIFOGLIO F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment[J]. Cell Mol Life Sci, 2010, 67(21): 3589-3608. DOI:10.1007/s00018-010-0486-4.

DAI N, CAO X J, LI M X, et al . Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer[J ] . PLoS ONE, 2013, 8(3): e58001.DOI:10.1371/journal.pone.0058001.

何乐, 杨宇馨, 张诗珩, 等.血清APE1自身抗体在结直肠癌诊断中的价值[J].第三军医大学学报, 2016, 38(11): 1297-1301. DOI:10.16016/j.1000-5404.201601165.

HE L, YANG Y X, ZHANG S H, et al . Diagnostic value of serum APE1 autoantibodies in colorectal cancer[J ] . J Third Mil Med Univ, 2016, 38(11): 1297-1301. DOI:10.16016/j.1000-5404.201601165.

ZHANG S H, HE L, DAI N, et al . Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients[J ] . Oncotarget, 2016, 7(47): 77482-77494. DOI:10.18632/oncotarget.13030.

GORGOULIS V G, VASSILIOU L V, KARAKAIDOS P, et al . Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions[J ] . Nature, 2005, 434(7035): 907-913. DOI:10.1038/nature03485.

LI Z, QING Y, GUAN W, et al . Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy[J ] . Cancer Chemother Pharmacol, 2014, 74(4): 777-786. DOI:10.1007/s00280-014-2562-1.

CHOI S, JOO H K, JEON B H. Dynamic regulation of APE1/ref-1 as a therapeutic target protein[J]. Chonnam Med J, 2016, 52(2): 75-80. DOI:10.4068/cmj.2016.52.2.75.

向德兵, 牟江洪, 谢家印, 等.大肠癌APE1的表达特点及临床意义[J].解放军医学杂志, 2006, 31(2): 115-116. DOI: 10.3321/j.issn:0577-7402.2006.02.011.

XIANG D B, MOU J H, XIE J Y, et al . Expression feature of APE1 and its clinical implication in colorectal carcinoma[J ] . Med J Chin PLA, 2006, 31(2): 115-116. DOI: 10.3321/j.issn:0577-7402.2006.02.011.

XIANG D B, CHEN Z T, WANG D, et al . Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensiti vity of human colorectal cancer cells to radiotherapy in vitro and in vivo [J ] . Cancer Gene Ther, 2008, 15(10): 625-635. DOI:10.1038/cgt.2008.30..

LAI C Y, HSIEH L L, TANG R, et al . Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan[J ] . World J Gastroenterol, 2016, 22(12): 3372-3380. DOI:10.3748/wjg.v22.i12.3372.

SHIN J H, CHOI S, LEE Y R, et al . APE1/ref-1 as a serological biomarker for the detection of bladder cancer[J ] . Cancer Res Treat, 2015, 47(4): 823-833. DOI:10.4143/crt.2014.074.

PASCUT D, SUKOWATI C H C, ANTONIALI G, et al . Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma[J ] . Oncotarget, 2019, 10(3): 383-394. DOI:10.18632/oncotarget.26555.

HUAJUN W, YING F, HONGXING Z, et al . Clinical value of combined detection of serum APE1-Aabs and CEACAM-1 in the diagnosis of colorectal cancer[J ] . Eur Rev Med Pharmacol Sci, 2018, 22(5): 1286-1289. DOI:10.26355/eurrev_201803_14469.

陈虞梅, 黄钢.肿瘤标志物CEA, CA50和CA19-9在大肠癌诊断中的意义[J].放射免疫学杂志, 2005, 18(1): 8-10.

CHEN Y M, HUANG G. Diagnostic significance of tumor markers CEA, CA50 and CA19-9 for colorectal cancer[J]. J Radioimmunol, 2005, 18(1): 8-10.

FAKIH M G, PADMANABHAN A. CEA monitoring in colorectal cancer. What you should know[J]. Oncology(Williston Park), 2006, 20(6):579-587.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

MiR-543/SNTB1 axis modulates immune microenvironment in colorectal cancer

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer

Preparation of nanosized hypoxia-inducible factor 1α inhibitor and its application in reversing chemoresistance in colorectal cancer cells

Diagnostic value of endoscopic LCPL sign for high-risk intestinal metaplasia in gastric mucosa

Construction of a diagnostic model for chronic mountain sickness among young male migrants to high-altitude areas

Related Author

ZHANG Min

LI Min

XIAO Meng

CHEN Cai

ZHENG Xiaoju

LEI Yuguang

ZHAO Wensi

SONG Jian

Related Institution

Department of Pathology, Xinyang Hospital of Traditional Chinese Medicine

School of Pharmaceutical Sciences， Xinyang Vocational and Technical College， Xinyang， Henan, Xinyang Hospital of Traditional Chinese Medicine

School of Medicine, Xinyang Hospital of Traditional Chinese Medicine

Department of Oncology, Renmin Hospital of Wuhan University

Department of Pharmacy, Renmin Hospital of Wuhan University

⁰